Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab safety in liver transplant recipients with advanced hepatocellular carcinoma
2024-514400-14-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of acute cellular rejection at 6 months. Planned start Jan 2026; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-514400-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514400-14-00.